

ORIGINAL ARTICLE

Double-blind randomised placebo-controlled trial of bolus-dose vitamin D₃ supplementation in adults with asthma (ViDiAs)

Adrian R Martineau,^{1,2} Beverley D MacLaughlin,¹ Richard L Hooper,¹ Neil C Barnes,^{1,2} David A Jolliffe,¹ Claire L Greiller,¹ Kate Kilpin,¹ David McLaughlin,¹ Gareth Fletcher,¹ Charles A Mein,¹ MIMOZA Hoti,¹ Robert Walton,¹ Jonathan Grigg,¹ Peter M Timms,³ Raj K Rajakulasingam,³ Angshu Bhowmik,³ Marion Rowe,³ Timothy R Venton,³ Aklak B Choudhury,⁴ David E Simcock,⁵ Zia Sadique,⁶ William R Monteiro,⁷ Christopher J Corrigan,⁸ Catherine M Hawrylowicz,⁸ Christopher J Griffiths^{1,2,8}

► Additional material is published online only. To view please visit the journal online (<http://dx.doi.org/10.1136/thoraxjnl-2014-206449>).

For numbered affiliations see end of article.

Correspondence to

Professor Adrian R Martineau, Centre for Primary Care and Public Health, Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, 58 Turner St, London E1 2AB, UK; a.martineau@qmul.ac.uk

Received 15 October 2014
Revised 21 January 2015
Accepted 27 January 2015
Published Online First
27 February 2015

ABSTRACT

Rationale Asthma exacerbations are commonly precipitated by viral upper respiratory infections (URIs). Vitamin D insufficiency associates with susceptibility to URI in patients with asthma. Trials of vitamin D in adults with asthma with incidence of exacerbation and URI as primary outcome are lacking.

Objective To conduct a randomised controlled trial of vitamin D₃ supplementation for the prevention of asthma exacerbation and URI (coprimary outcomes).

Measurements and methods 250 adults with asthma in London, UK were allocated to receive six 2-monthly oral doses of 3 mg vitamin D₃ (n=125) or placebo (n=125) over 1 year. Secondary outcomes included asthma control test and St George's Respiratory Questionnaire scores, fractional exhaled nitric oxide and concentrations of inflammatory markers in induced sputum. Subgroup analyses were performed to determine whether effects of supplementation were modified by baseline vitamin D status or genotype for 34 single nucleotide polymorphisms in 11 vitamin D pathway genes.

Main results 206/250 participants (82%) were vitamin D insufficient at baseline. Vitamin D₃ did not influence time to first severe exacerbation (adjusted HR 1.02, 95% CI 0.69 to 1.53, p=0.91) or first URI (adjusted HR 0.87, 95% CI 0.64 to 1.16, p=0.34). No clinically important effect of vitamin D₃ was seen on any of the secondary outcomes listed above. The influence of vitamin D₃ on coprimary outcomes was not modified by baseline vitamin D status or genotype.

Conclusions Bolus-dose vitamin D₃ supplementation did not influence time to exacerbation or URI in a population of adults with asthma with a high prevalence of baseline vitamin D insufficiency.

Trial registration number NCT00978315 (ClinicalTrials.gov).

INTRODUCTION

Acute exacerbations are the major cause of morbidity and mortality in patients with asthma. Viral upper respiratory infections (URIs) are major

Key messages

What is the key question?

- Does vitamin D₃ supplementation prevent asthma exacerbation or upper respiratory infection (URI) in adults with inhaled corticosteroid-treated asthma?

What is the bottom line?

- In patients with a high prevalence of vitamin D insufficiency at baseline, vitamin D₃ supplementation did not influence time to exacerbation or URI or concentrations of inflammatory markers in induced sputum; effects of the intervention were not modified by baseline vitamin D status or by polymorphisms in the vitamin D pathway.

Why read on?

- This is the first clinical trial in adults to investigate the effects of vitamin D₃ supplementation on incidence of asthma exacerbation and URI as primary outcomes.

precipitants, but interventions to prevent these are lacking.¹ Numerous observational studies have reported associations between inadequate vitamin D status (serum 25-hydroxyvitamin D (25(OH)D) concentration <75 nmol/L) and susceptibility to URI²; these are particularly strong in patients with asthma.³ In vitro, vitamin D metabolites favourably modulate the immune response to respiratory viruses⁴ and enhance responsiveness to corticosteroids for production of the anti-inflammatory cytokine interleukin-10.⁵ Two small trials of vitamin D supplementation in children with asthma treated with inhaled corticosteroids (ICS) have reported reduced rates of exacerbation among participants randomised to the intervention arm.^{6,7}

Recently, a trial of vitamin D supplementation conducted in adults reported a trend towards



CrossMark

To cite: Martineau AR, MacLaughlin BD, Hooper RL, et al. *Thorax* 2015;**70**:451–457.

protection against asthma exacerbation in the intervention arm as a secondary outcome (adjusted HR 0.63, 95% CI 0.39 to 1.01).⁸ Trials of vitamin D in adults with asthma with incidence of exacerbation and URI as primary outcome are still lacking however. Moreover, no studies have been conducted to determine the influence of vitamin D on FE_{NO} or concentrations of inflammatory mediators in induced sputum, or to investigate whether genetic factors influence responses to vitamin D supplementation in asthma, as suggested by an observational study.⁹ We therefore conducted a double-blind randomised placebo-controlled trial of vitamin D₃ supplementation in adults with ICS-treated asthma to test the hypothesis that this intervention reduces incidence of URI and severe exacerbations in this population, including measures of lower airway inflammation as secondary outcomes. Prespecified subgroup analyses were performed to investigate whether 34 single nucleotide polymorphisms in 11 vitamin D pathway genes modified the effects of vitamin D supplementation on clinical outcomes. In the absence of a consensus on 25(OH)D thresholds required for protection against disease, we deliberately enrolled patients with a broad range of baseline 25(OH)D values so that prespecified interaction analyses could be conducted to determine whether the effects of supplementation varied according to baseline vitamin D status. A bolus dosing regimen was used to achieve rapid correction of vitamin D deficiency among participants in the intervention arm, and to allow supervised administration of trial medication to maximise adherence.

METHODS

Participants

Adult patients with a medical record diagnosis of asthma treated with ICS were identified by searching databases at 60 general practices and at asthma clinics in two Acute National Health Service Trusts in London, UK, and invited for screening. Principal exclusion criteria were age <16 years or >80 years; tobacco smoking history >15 pack-years; medical record diagnosis of COPD; and failure to exhibit significant variability/reversibility in airway obstruction. Written informed consent was obtained from all participants before enrolment.

Procedures

Participants attending screening visits completed the St George's Respiratory Questionnaire (SGRQ),¹⁰ the EuroQoL-5D questionnaire¹¹ and the Asthma Control Test (ACT)¹² and underwent a baseline clinical assessment incorporating spirometry, measurement of FE_{NO} and collection of a blood sample. A subset of 50 participants was invited to undergo sputum induction with hypertonic saline. Participants fulfilling eligibility criteria entered a run-in period of at least 2 weeks, during which they were asked to complete a symptom diary on a daily basis (see online figure E1). Eligible patients were randomly assigned to receive six 2-monthly oral doses of 6 mL Vigantol oil (Merck Serono, Darmstadt, Germany) containing 3 mg (120 000 IU) vitamin D₃, or 6 mL organoleptically identical placebo (Miglyol oil, Caesar and Loretz, Hilden, Germany) with allocation ratio 1:1. Randomisation was assigned by permuted blocks of 10 and stratified according to (A) British Thoracic Society treatment step (2–3 vs 4–5) and (B) inclusion in versus exclusion from the induced sputum substudy.

Participants completed study diaries daily for 12 months. Five further doses of study medication were administered at 2-monthly intervals following the first dose. Face-to-face follow-up visits were performed at 2 months, 6 months and 12 months of follow-up.

Coprimary end points for the trial were time to first severe asthma exacerbation and time to first URI. Severe asthma exacerbation was defined as deterioration in asthma resulting in (A) treatment with oral corticosteroids, or (B) hospital admission or emergency department treatment, or (C) decrease in the morning peak expiratory flow rate (PEFR) to more than 25% below the mean run-in value on two or more consecutive days.¹³ URI was defined as influenza-like illness¹⁴ or as a cold with symptom scores meeting modified Jackson criteria.¹⁵

Secondary end points were peak values and areas under the curve for symptom scores during severe exacerbation/URI; proportion of days with poor asthma control; proportion of nights with awakenings due to asthma symptoms; time to unscheduled healthcare attendance and use of antibiotics for exacerbation/URI; ACT and SGRQ scores, FE_{NO} concentration, daily ICS doses, % predicted FEV₁, PEF, use of inhaled relief medication and induced sputum differential cell count and supernatant inflammatory profiles at 2 months, 6 months and 12 months; trough serum concentrations of 25(OH)D and parathyroid hormone (PTH) at 2 months and 12 months; and health economic outcomes (costs of exacerbations and URI, quality-adjusted life years and incremental net benefit over 1 year).

Sample size and statistical analysis

Assuming a median time to event of 120 days¹⁶ we calculated that 200 participants (100 in each group) would need to be randomised in order to detect a 60 day difference in median time to event between intervention and control groups with 80% power using a two-sided test at the 5% significance level.¹⁷ A total of 250 participants were recruited in order to allow for 20% loss to follow-up.

Analysis was by intention-to-treat: all participants who took at least one dose of study medication were included in efficacy and safety analyses. Significance was tested at the 5% level. Time-to-event outcomes were analysed using Cox regression adjusted for stratification factors. Subgroup analyses were conducted to determine whether the effect of vitamin D₃ supplementation on coprimary outcomes was modified by baseline vitamin D status (using serum 25(OH)D thresholds of 50 nmol/L and 75 nmol/L) or genotype.

Further details of Methods are presented in online supplementary information.

RESULTS

Five hundred and ninety adults with a medical record diagnosis of asthma were invited to participate in the trial. Of these, 297 attended a screening visit and were assessed for eligibility between 27 August 2009 and 25 June 2012: 37 were ineligible to participate and 10 were eligible but declined randomisation. The remaining 250 participants were randomised to intervention versus control arms of the trial in equal numbers: all received at least one dose of study medication, and were included in the intention-to-treat analysis (figure 1). Clinical and demographic characteristics of randomised participants were comparable for intervention versus control groups (table 1). The majority (206/250, 82%) had inadequate vitamin D status (serum 25(OH)D <75 nmol/L) at baseline, and participants had a high rate of events requiring oral corticosteroids and/or an increase in ICS dose in the year preceding enrolment (median 2.0 episodes, IQR 1.0 to 3.0). The trial ended on the date of the final study visit of the final participant undergoing follow-up.

Allocation to vitamin D₃ versus placebo did not influence time to first severe asthma exacerbation (adjusted HR 1.02,




Figure 1 Trial profile.

95% CI 0.69 to 1.53, $p=0.91$) or time to first URI (adjusted HR 0.87, 95% CI 0.64 to 1.16, $p=0.34$; [figure 2](#), [table 2](#)). Neither did it influence the annual rate of severe exacerbations or URI; the proportion of participants experiencing either outcome; or the peak severity or symptom score area under the curve for either event ([table 2](#), see online figure E2, supplementary information). No effect of the intervention was seen on ACT scores, other measures of asthma symptom control, FEV₁, PEFR or FE_{NO} ([table 2](#)). Allocation to the intervention arm of the trial resulted in a significant increase in serum 25(OH)D concentration (mean 23.0 nmol/L increase at 12 months, $p<0.001$, [table 2](#)). This was associated with suppressed serum PTH concentration (mean 0.89 pmol/L decrease at 12 months, $p=0.02$), but not with a difference in serum corrected calcium concentration (see online table E5, supplementary information).

Administration of vitamin D₃ modestly improved respiratory quality of life as evidenced by adjusted interarm differences in total SGRQ score of -3.9 points at 2 months ($p=0.005$), -3.7 points at 6 months ($p=0.038$) and -3.3 points at 12 months ($p=0.060$; p for allocation-time interaction= 0.026 ; [table 2](#), see online figure E3, supplementary information). These reductions were associated with statistically significant decreases in component scores for the impacts dimension of the SGRQ at 2 months ($p=0.05$) and 6 months ($p=0.005$; p for allocation-time interaction= 0.030 , see online table E2, figure E3, supplementary information). No differences in EQ5D scores were observed between arms (see online table E3, supplementary information). Allocation to vitamin D₃ versus placebo did not influence differential white cell counts or inflammatory profile in induced sputum (see online table E4, supplementary information).

Day-to-day values for PEFR, asthma symptom score, short-acting bronchodilator use or the percentage of participants woken at night or experiencing poor asthma control days did not fluctuate in relation to the timing of administration of intermittent bolus doses of study medication (see online figure E4, supplementary information). Allocation to vitamin D₃ versus placebo did not influence use of asthma medications or antimicrobials (see online table E6, supplementary information) or health service uptake (see online table E7, supplementary

Table 1 Baseline characteristics by allocation

	Vitamin D ₃ (n=125)*	Placebo (n=125)*
Age, years	49.4 (14.8)	46.4 (13.8)
Sex		
Male, n (%)	55 (44%)	54 (43%)
Female, n (%)	70 (56%)	71 (57%)
Ethnicity		
White, n (%)	103 (82%)	99 (79%)
Black/Black British, n (%)	10 (8%)	12 (10%)
Other, n (%)	12 (10%)	14 (11%)
Body mass index ≥ 30 kg/m ²	36 (29%)	29 (23%)
Current smoker, n (%)	8 (6%)	9 (7%)
BTS step of treatment at enrolment		
2: Regular preventer therapy	58 (46%)	56 (45%)
3: Initial add-on therapy	49 (39%)	54 (43%)
4: Persistent poor control	17 (14%)	15 (12%)
5: Continuous/frequent use of OCS	1 (1%)	0 (0%)
Medication use		
ICS dose at entry in betamethasone equivalents, † μ g	668 (559)	783 (693)
Inhaled LABA use, ‡ n (%)	63 (50%)	67 (54%)
Leukotriene antagonist use, n (%)	15 (12%)	14 (11%)
Vaccine uptake		
Influenza vaccine, n (%)	106 (85%)	109 (87%)
Pneumococcal vaccine, n (%)	50 (40%)	31 (25%)
Median no. of URI/exacerbations requiring OCS or increase in ICS in previous 12 months (IQR)	2.0 (1.0 to 3.0)	2.0 (1.0 to 3.0)
Median no. of days since last exacerbation/URI requiring OCS or increase in ICS (IQR)	122 (69 to 237)	132 (75 to 248)
Median asthma duration, years (IQR)	25 (14 to 36)	23 (14 to 32)
Managed exclusively in primary care, n (%)	110 (88%)	111 (89%)
ACT score (SD)	19.2 (3.9)	18.9 (3.9)
Median SGRQ score (IQR)	23.7 (14.4 to 37.4)	20.7 (11.1 to 35.3)
Eczema, n (%)	54 (43%)	48 (38%)
Allergic rhinitis, n (%)	89 (71%)	95 (76%)
Peripheral blood eosinophil count $\times 10^9/L$	0.28 (0.22)	0.29 (0.23)
Peripheral blood eosinophil count $>0.5 \times 10^9/L$, n (%)	11 (9%)	10 (8%)
Prebronchodilator FEV ₁ , % predicted	82.0 (18.7)	81.0 (20.4)
Morning PEFR during run-in period, L/min	383 (106)	379 (123)
FE _{NO} , ppb	38.1 (29.1)	37.0 (26.0)
Vitamin D status		
Serum 25(OH)D concentration, nmol/L	49.8 (25.2)	49.4 (24.2)
Serum 25(OH)D <75 nmol/L	105 (84%)	101 (81%)
Serum 25(OH)D <50 nmol/L	72 (58%)	72 (58%)
Serum 25(OH)D <25 nmol/L, n (%)	19 (15%)	17 (14%)
Randomised to induced sputum substudy	24 (19%)	26 (21%)

*Mean (SD) presented unless stated otherwise.


†1 μ g betamethasone assumed equivalent to 1 μ g budesonide, 0.5 mcg fluticasone dipropionate and 0.75 mcg ciclesonide.

‡Includes combinations of ICS/LABA and LABA.

25(OH)D, 25-hydroxyvitamin D; ACT, asthma control test; BTS, British Thoracic Society guidelines; ICS, inhaled corticosteroids; LABA, long-acting β -2 agonist; OCS, oral corticosteroids; PEFR, peak expiratory flow rate; ppb, parts per billion; SGRQ, St George's Respiratory Questionnaire; URI, upper respiratory infection.

information). Neither did it influence work absence due to asthma symptoms or respiratory infections (see online table E8, supplementary information) or health economic outcomes (see

Figure 2 Coprimary outcomes by allocation. Time to first severe asthma exacerbation (A) and first upper respiratory infection (URI, B) by allocation. Numbers of participants yet to experience each outcome (number at risk) at 0 weeks, 13 weeks, 26 weeks, 39 weeks and 52 weeks are shown. Solid line, vitamin D₃; dotted line, placebo.



online table E9, supplementary information). The cost-effectiveness acceptability curve displayed in online figure E5, supplementary information, shows that the probability that vitamin D₃ versus placebo is cost-effective is around 70% at a realistic willingness to pay (£20 000) for a quality-adjusted life year gain. Prespecified subgroup analyses revealed no evidence of effect modification on coprimary outcomes according to baseline vitamin D status (see online table E10, supplementary information). After correction for multiple analyses, none of the single nucleotide polymorphism investigated were found to modify the effect of supplementation on risk of severe exacerbation or URI (see online table E11, supplementary information).

Twenty-three serious adverse events were reported in 20/250 participants receiving at least one dose of study medication; one participant died during the study, following a road traffic accident (see online table E12, supplementary information). No serious adverse event was attributed to study medication. A total of 1283 non-serious adverse events were reported in 240/250 participants: these were equally distributed between study arms (see online table E13, supplementary information). No hypercalcaemia was seen.

DISCUSSION

We report findings of the first trial of bolus dose vitamin D supplementation for the prevention of exacerbation and URI in adult patients with asthma. No effect of the intervention was seen on either coprimary outcome, despite a high prevalence of vitamin D insufficiency at baseline. Of 16 secondary outcomes investigated, only one—respiratory quality of life, as measured by the SGRQ—showed a statistically significant difference between arms, but this was just less than the 4-point minimum clinically important difference for this instrument.¹⁸ Prespecified subgroup analyses demonstrated no statistically significant evidence of effect modification by clinical or genetic characteristics after correction for multiple analyses.

The results of our trial support and extend the findings of the VIDA trial, recently reported by Castro *et al.*⁸ These investigators studied a population of patients with asthma with baseline 25(OH)D <75 nmol/L and reported no effect of vitamin D supplementation on a primary outcome of treatment failure. Subgroup analysis restricted to the 82% of vitamin D₃ supplementation in adults with asthma trial participants with baseline 25(OH)D <75 nmol/L revealed no effect of the intervention on either of our coprimary outcomes. Our trial may therefore be regarded as confirming the findings of the VIDA study.

Although primary outcomes for our trial were null, we did observe a modest but statistically significant improvement in respiratory quality of life among participants in the intervention arm, as measured by the total SGRQ score; this was associated with decreases in the impacts scores component of the SGRQ. One of the correlates of the impacts component of the SGRQ is

exercise performance, and the favourable effects of vitamin D supplementation on muscle function in deficient subjects are well documented:¹⁹ it may be, therefore, that positive effects of vitamin D₃ supplementation on participants' quality of life were mediated by enhancing muscle function; they were not mediated via improved control of asthma symptoms, as the intervention did not influence days in which asthma was poorly controlled, nights with awakenings or ACT scores. However, the possibility of a positive finding arising from type 1 error cannot be ruled out, given the large number of prespecified secondary outcomes in this study. This finding should therefore be regarded as exploratory.

Our trial has several strengths. Inadequate vitamin D status was highly prevalent among the study population at baseline, and participants had significant potential for improvement in asthma control at enrolment as evidenced by high FE_{NO} at baseline. We gave a generous dose of vitamin D₃, equivalent to 2000 IU (50 µg) per day—more than three times the recommended dietary allowance for adults proposed by the US Institute of Medicine.²⁰ The intermittent bolus dosing regimen we employed allowed us to achieve a high degree of compliance with the intervention (3/6 doses were directly observed and 3/6 were supervised telephonically), while the use of daily symptom diaries allowed us to characterise participants' symptoms in fine detail. Our trial complements the VIDA trial⁸ by providing new data on efficacy of a bolus dosing regimen administered for a year to patients with a wide range of baseline serum 25(OH)D concentrations on additional outcomes including incidence of URI, other measures of airway inflammation (exhaled nitric oxide and induced sputum supernatant inflammatory profiles), potential genetic effect modifiers and health economic outcomes.

Our trial also has some limitations. Patients with URI symptoms were not sampled for detection of pathogens; we have previously validated the symptomatic definition of URI employed in this study against PCR in another trial however.²¹ A minority (32%) of asthma exacerbations in our trial were associated with URI—a somewhat lower proportion than the 44% reported elsewhere.²² Our trial was conducted in an urban setting, and participants had a relatively high prevalence of allergic rhinitis and eczema at baseline. Allergens and particulates may therefore have precipitated a significant number of exacerbations in our study population: if vitamin D only prevents exacerbation precipitated by URI, then this phenomenon could have contributed to our negative findings. Although 77% of participants in our trial experienced a URI, only 44% experienced a severe exacerbation; our study may therefore have lacked power to detect small or moderate effects of the intervention on exacerbation risk.

Another potential limitation relates to the intermittent bolus dosing regimen that we employed. Although this was reasonably effective in correcting vitamin D deficiency (80% of participants

Table 2 Outcomes by allocation

	Vitamin D ₃ (n=125)	Placebo (n=125)	Adjusted HR/incidence rate ratio/odds ratio/mean difference/ratio of geometric means (95% CI)*	p Value
Severe asthma exacerbation				
Median time to first severe exacerbation, days (IQR)	– (192 to –)	– (136 to –)	1.02 (0.69 to 1.53)	0.91
Rate of severe exacerbations per participant-year	136/117.4=1.16	145/116.7=1.24	0.93 (0.57 to 1.51)	0.77
Proportion of participants with ≥1 severe exacerbation (%)†	50/108 (46%)	47/114 (41%)	1.20 (0.70 to 2.05)	0.52
Mean peak asthma symptom score per severe exacerbation‡	1.60 (1.22)	1.67 (1.13)	–0.13 (–0.52 to 0.26)	0.51
Mean area under the curve per severe exacerbation, asthma symptom score§	26.2 (23.7)	24.5 (18.2)	–0.44 (–8.65 to 7.76)	0.92
Proportion of exacerbations associated with URI (%)	45/136 (34%)	44/145 (30%)	1.04 (0.40 to 2.70)	0.96
URI				
Median time to first URI, days (IQR)	128 (42 to –)	112 (40 to 309)	0.87 (0.64 to 1.16)	0.34
Proportion of participants with ≥1 URI (%)†	85/115 (74%)	93/117 (79%)	0.71 (0.38 to 1.32)	0.28
Rate of URI per participant-year	234/117.4=1.99	250/116.7=2.14	0.89 (0.70 to 1.14)	0.35
Mean peak Jackson symptom score per URI¶	11.5 (5.1)	10.5 (4.7)	0.76 (–0.47 to 1.99)	0.23
Mean area under the curve per URI, Jackson symptom score**	105.0 (67.0)	90.6 (69.9)	5.1 (–13.5 to 23.8)	0.59
Days in which asthma is poorly controlled††				
Rate per participant-year	4486/117.4=38.2	4049/116.7=34.7	1.07 (0.75 to 1.51)	0.72
Nights with awakenings due to asthma symptoms				
Rate per participant-year	3166/117.4=27.0	2702/116.7=23.2	1.14 (0.69 to 1.86)	0.61
ACT score				
Mean (SD)				
2 months	20.1 (3.9)	19.5 (4.4)	0.52 (–0.27 to 1.31)	0.56‡‡
6 months	20.6 (3.5)	20.6 (3.8)	0.00 (–0.81 to 0.81)	
12 months	20.4 (4.0)	20.4 (4.2)	0.00 (–0.82 to 0.82)	
FEV₁ (% predicted)				
Mean (SD)				
2 months	81.5 (18.7)	81.6 (20.4)	–0.95 (–3.71 to 1.81)	0.53‡‡
6 months	80.6 (21.0)	81.0 (20.8)	–1.56 (–4.37 to 1.26)	
12 months	81.6 (18.5)	80.1 (22.8)	0.44 (–2.42 to 3.30)	
Morning PEFr (mean over period since preceding study visit)				
Mean (SD)				
2 months	380.6 (108.6)	375.2 (121.2)	–0.2 (–8.1 to 7.7)	0.38‡‡
6 months	385.0 (118.6)	382.9 (122.4)	–5.3 (–13.4 to 2.8)	
12 months	388.1 (116.8)	387.7 (122.9)	–5.4 (–13.6 to 2.8)	
Fractional exhaled nitric oxide, ppb				
Mean (SD)				
2 months	36.1 (25.7)	36.5 (31.7)	–1.3 (–6.4 to 3.8)	0.71‡‡
6 months	36.7 (28.8)	34.6 (32.4)	1.6 (–3.7 to 6.8)	
12 months	37.5 (26.9)	38.5 (36.9)	–1.4 (–6.8 to 3.9)	

Continued

Table 2 Continued

	Vitamin D ₃ (n=125)	Placebo (n=125)	Adjusted HR/incidence rate ratio/odds ratio/mean difference/ratio of geometric means (95% CI)*	p Value
SGRQ total score§§				
Median (IQR)				
2 months	16.0 (8.5 to 26.2)	17.3 (8.9 to 30.1)	0.87 (0.79 to 0.96)¶¶¶	0.005***
6 months ²¹	14.7 (7.5 to 24.4)	14.6 (7.1 to 29.7)	0.90 (0.82 to 0.99)†††	0.038***
12 months ²³	13.6 (7.1 to 24.7)	13.9 (7.2 to 25.0)	0.91 (0.82 to 1.00)‡‡‡	0.060***
Serum 25(OH)D, nmol/L				
Mean (SD)				
2 months	61.2 (22.1)	48.5 (25.0)	12.5 (7.6 to 17.3)	<0.001§§§
12 months	69.4 (21.0)	46.5 (24.6)	23.0 (17.9 to 28.0)	<0.001§§§
Participants with 25(OH)D ≥50 nmol/L				
n (%)				
2 months	88/121 (73%)	52/119 (44%)	1.83 (1.04 to 2.62)	<0.001§§§
12 months	86/107 (80%)	43/110 (39%)	2.72 (1.83 to 3.61)	<0.001§§§

*Adjusted for stratification factors, that is, British Thoracic Society treatment step (2/3 vs 4/5) and inclusion in vs exclusion from sputum induction substudy.

†This analysis excludes participants who withdrew from the trial without experiencing this event prior to withdrawal.

‡Asthma symptoms scored from 0 (no symptoms) to 3 (severe symptoms).

§Area under the curve calculated for asthma symptom score from 7 days preonset of exacerbation to 20 days postonset.

¶Jackson symptoms (sneezing, sore throat, headache, subjective sensation of fever or chilliness, malaise, nasal discharge, nasal obstruction, cough) each scored from 0 (no symptoms) to 3 (severe symptoms) and summed for each day of the URI.

**Area under the curve calculated for total Jackson symptom score from 7 days preonset of URI to 20 days postonset.

††Poorly controlled asthma day defined as a 24-h period in which diary recorded waking at night due to asthma symptoms, morning PEFR ≥20% below mean run-in value or ≥2 uses of reliever medication above median run-in value; days included in a severe exacerbation are excluded from the count of poorly controlled asthma days.

‡‡p Value for allocation-time interaction presented; p values for effect of allocation at individual time points are not reported where p for allocation-time interaction ≥0.05.

§§A small constant (1.0) was added to each value prior to log transforming for the regression analysis, to avoid taking logs of zero.

¶¶Ratio of geometric means is presented; adjusted mean difference=3.9 points.

***p For allocation-time interaction=0.026.

†††Ratio of geometric means is presented; adjusted mean difference=3.7 points.

‡‡‡Ratio of geometric means is presented; adjusted mean difference=3.3 points.

§§§p For allocation-time interaction <0.001.

25(OH)D, 25-hydroxyvitamin D; ACT, asthma control test; PEFR, peak expiratory flow rate; ppb, parts per billion; SGRQ, St George's Respiratory Questionnaire; URI, upper respiratory infection.

in the intervention arm had 25(OH)D levels ≥ 50 nmol/L at 12 months, as compared with 39% of those in the placebo arm, $p < 0.001$, the interarm difference in serum 25(OH)D concentrations at 12 months was modest (22 nmol/L). It should be noted, however, that serum 25(OH)D concentrations at this time point represent 'trough levels': pharmacokinetic studies of the 25(OH)D response to bolus-dose vitamin D supplementation indicate that concentrations peak at 1 week post dose and remain high for several weeks thereafter;²³ the difference in vitamin D status between arms in our trial will therefore have been significantly higher than 22 nmol/L for much of the inter-dosing period. This is reflected in the fact that serum PTH concentrations were significantly lower in the intervention versus the control arm of the trial at 1 year.

While intermittent bolus-dosing with vitamin D can prevent bone fractures,²⁴ some have proposed that it may be less effective than daily dosing for inducing non-classical actions of vitamin D.^{25–26} However, we^{27–28} and others²⁹ have previously shown favourable effects of bolus-dose vitamin D supplementation on outcomes relating to respiratory infection. Nevertheless, we cannot exclude the possibility that results of the vitamin D₃ supplementation in adults with asthma trial might have been different if vitamin D had been administered on a daily basis, and trials comparing the effects of daily versus intermittent dosing are needed to address this issue. Pending the conduct of such studies, pooling of existing trial data for individual patient data meta-analysis has potential to increase power to detect effects of vitamin D supplementation on exacerbation risk, and thereby to advance the field.

Author affiliations

¹Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK

²Asthma UK Centre for Applied Research, Blizard Institute, Queen Mary University of London, London, UK

³Homerton University Hospital, London, UK

⁴Queen's Hospital, Rom Valley Way, Romford, London, UK

⁵Royal London Hospital, London, UK

⁶London School of Hygiene and Tropical Medicine, London, UK

⁷NIHR Leicester Respiratory Biomedical Research Unit, Glenfield Hospital, Leicester, UK

⁸MRC and the Asthma UK Centre for Allergic Mechanisms in Asthma, King's College London, London, UK

Acknowledgements The authors thank the members of the Data Monitoring Committee, Guy E Thwaites (Chair), Brenda E Jones and Tuan Q Phung. The authors also thank clinical and administrative staff at all General Practices acting as participant identification centres; pharmacy staff at the Royal London Hospital for overseeing dispensing of study medication; and all the patients who participated in the trial.

Contributors ARM had the original idea for the study. ARM, BDM, NCB, DAJ, RW, PMT, CJC, CMH and CJG contributed to study design. ARM, BDM, NCB, DAJ, KK, GF, JG, RKR, AB, ABC, DES, CJC and CJG participated in implementation of the trial. DAJ, CLG, CAM, MH, RW, PMT, MR, TRV and WRM developed and performed laboratory assays. DM validated diary records of health economic outcomes. ARM, RLH and DAJ contributed to clinical data analysis. ZS performed health economic analysis. ARM wrote the first draft of the manuscript; all other authors critically reviewed it and approved the final version.

Funding This is a summary of independent research funded by the National Institute for Health Research (NIHR)'s Programme Grants for Applied Research Programme (ref RP-PG-0407-10398).

Competing interests None.

Ethics approval East London and The City Research Ethics Committee 1 (ref O9/H0703/67).

Provenance and peer review Not commissioned; internally peer reviewed.

Data sharing statement Data from the study will be made publicly available in a data repository on publication of this trial report.

REFERENCES

- Jackson DJ, Sykes A, Mallia P, *et al*. Asthma exacerbations: origin, effect, and prevention. *J Allergy Clin Immunol* 2011;128:1165–74.
- Jolliffe DA, Griffiths CJ, Martineau AR. Vitamin D in the prevention of acute respiratory infection: systematic review of clinical studies. *J Steroid Biochem Mol Biol* 2013;136:321–9.
- Ginde AA, Mansbach JM, Camargo CA Jr. Association between serum 25-hydroxyvitamin D level and upper respiratory tract infection in the Third National Health and Nutrition Examination Survey. *Arch Intern Med* 2009;169:384–90.
- Hansdottir S, Monick MM, Lovan N, *et al*. Vitamin D decreases respiratory syncytial virus induction of NF-kappaB-linked chemokines and cytokines in airway epithelium while maintaining the antiviral state. *J Immunol* 2010;184:965–74.
- Xystrakis E, Kusumakar S, Boswell S, *et al*. Reversing the defective induction of IL-10-secreting regulatory T cells in glucocorticoid-resistant asthma patients. *J Clin Invest* 2006;116:146–55.
- Majak P, Olszowiec-Chlebna M, Smejda K, *et al*. Vitamin D supplementation in children may prevent asthma exacerbation triggered by acute respiratory infection. *J Allergy Clin Immunol* 2011;127:1294–6.
- Yadav M, Mittal K. Effect of vitamin D supplementation on moderate to severe bronchial asthma. *Indian J Pediatr* 2014;81:650–4.
- Castro M, King TS, Kunselman SJ, *et al*. Effect of vitamin D₃ on asthma treatment failures in adults with symptomatic asthma and lower vitamin D levels: the VIDA randomized clinical trial. *JAMA* 2014;311:2083–91.
- Du R, Lironjua AA, Tantisira KG, *et al*. Genome-wide association study reveals class I MHC-restricted T cell-associated molecule gene (CRTAM) variants interact with vitamin D levels to affect asthma exacerbations. *J Allergy Clin Immunol* 2012;129:368–73, 73.e1–5.
- Jones PW, Quirk FH, Baveystock CM, *et al*. A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. *Am Rev Respir Dis* 1992;145:1321–7.
- EuroQol Group. EuroQol—a new facility for the measurement of health-related quality of life. *Health Policy* 1990;16:199–208.
- Nathan RA, Sorkness CA, Kosinski M, *et al*. Development of the asthma control test: a survey for assessing asthma control. *J Allergy Clin Immunol* 2004;113:59–65.
- O'Byrne PM, Barnes PJ, Rodriguez-Roisin R, *et al*. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. *Am J Respir Crit Care Med* 2001;164(8 Pt 1):1392–7.
- Payne L, Kuhlmann-Berenzon S, Ekdahl K, *et al*. 'Did you have flu last week?' A telephone survey to estimate a point prevalence of influenza in the Swedish population. *Euro Surveill* 2005;10:241–4.
- Jackson GG, Dowling HF, Spiesman IG, *et al*. Transmission of the common cold to volunteers under controlled conditions. I. The common cold as a clinical entity. *Arch Intern Med* 1958;101:267–78.
- Griffiths C, Foster G, Barnes N, *et al*. Specialist nurse intervention to reduce unscheduled asthma care in a deprived multiethnic area: the east London randomised controlled trial for high risk asthma (ELECTRA). *BMJ* 2004;328:144.
- Schoenfeld DA, Richter JR. Nomograms for calculating the number of patients needed for a clinical trial with survival as an endpoint. *Biometrics* 1982;38:163–70.
- Jones PW. St. George's Respiratory Questionnaire: MCID. *COPD* 2005;2:75–9.
- Pfeifer M, Begerow B, Minne HW. Vitamin D and muscle function. *Osteoporos Int* 2002;13:187–94.
- Institute of Medicine. *Dietary reference intakes for calcium and vitamin D*. Washington DC: National Academy Press, 2011.
- Martineau AR, Hanifa Y, Hooper RL, *et al*. Increased risk of upper respiratory infection with addition of intermittent bolus-dose vitamin D supplementation to a daily low-dose regimen. *Thorax* 2013;68(Suppl 3):A64.
- Nicholson KG, Kent J, Irelhad DC. Respiratory viruses and exacerbations of asthma in adults. *Br Med J* 1993;307:982–6.
- Ilahi M, Armas LA, Heaney RP. Pharmacokinetics of a single, large dose of cholecalciferol. *Am J Clin Nutr* 2008;87:688–91.
- Trivedi DP, Doll R, Khaw KT. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. *BMJ* 2003;326:469.
- Vieth R. How to optimize vitamin D supplementation to prevent cancer, based on cellular adaptation and hydroxylase enzymology. *Anticancer Res* 2009;29:3675–84.
- Hollis BW, Wagner CL. The role of the parent compound vitamin D with respect to metabolism and function: why clinical dose intervals can affect clinical outcomes. *J Clin Endocrinol Metab* 2013;98:4619–28.
- Martineau AR, Wilkinson RJ, Wilkinson KA, *et al*. A single dose of vitamin D enhances immunity to mycobacteria. *Am J Respir Crit Care Med* 2007;176:208–13.
- Martineau AR, James WY, Hooper RL, *et al*. Vitamin D supplementation in patients with chronic obstructive pulmonary disease (ViDiCO): a multicentre, double-blind, randomised controlled trial. *Lancet Respir Med* 2015;3:120–30.
- Lehouck A, Mathieu C, Carremans C, *et al*. High doses of vitamin D to reduce exacerbations in chronic obstructive pulmonary disease: a randomized trial. *Ann Intern Med* 2012;156:105–14.